MedTrace Logo

Efficacy of Surgical Glove-Compression Therapy As a Prevention of Paclitaxel-Induced Peripheral Neuropathy

NCT06763575 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-01-08

No results posted yet for this study

Summary

The aim of this randomized controlled trial (RCT) is to compare the incidence of paclitaxel-induced grade 2 or higher sensory peripheral neuropathy, evaluated using the CTCAE version 5.0, between patients receiving surgical glove-compression therapy (SGCT) and those in the control group.

The main question is whether SGCT is effective in preventing paclitaxel-induced sensory peripheral neuropathy.

* Intervention group: receive SGCT.
* Control group: receive non-compressive plastic gloves.

Conditions

  • Paclitaxel-induced Peripheral Neuropathy

Interventions

DEVICE

Surgical Glove-Compression Therapy

In the intervention group, patients wore double-layered surgical gloves, one size smaller than measured, covered by large cotton gloves on both hands, for 30 minutes before, during, and after chemotherapy.

DEVICE

non-compressive plastic gloves

In the control group, patients wore non-compressive plastic gloves, covered by large cotton gloves on both hands, for 30 minutes before, during, and after chemotherapy.

Sponsors & Collaborators

  • Department of Medical Services Ministry of Public Health of Thailand

    lead OTHER_GOV

Principal Investigators

  • Sunatee Sa-nguansai, M.D. · Department of Medical Services Ministry of Public Health of Thailand

  • Saowani Thantaviraya, M.D. · Department of Medical Services Ministry of Public Health of Thailand

  • Kunlatida Maneenil, M.D. · Department of Medical Services Ministry of Public Health of Thailand

  • Piyawan Tienchaiananda, M.D. · Department of Medical Services Ministry of Public Health of Thailand

  • Songwit Payapwattanawong, M.D. · Department of Medical Services Ministry of Public Health of Thailand

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2026-01-01
Completion
2026-06-01

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06763575 on ClinicalTrials.gov